Craig Greven to Angiogenesis Inhibitors
This is a "connection" page, showing publications Craig Greven has written about Angiogenesis Inhibitors.
Connection Strength
0.234
-
Kurup SK, Gee C, Greven CM. Intravitreal methotrexate in therapeutically resistant exudative age-related macular degeneration. Acta Ophthalmol. 2010 Jun; 88(4):e145-6.
Score: 0.087
-
Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007 Oct; 114(10):1860-7.
Score: 0.076
-
Singer MA, Miller DM, Gross JG, Greven CM, Kapik B, Bailey C, Ghanchi F, Kuppermann BD. Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 µg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I). Ophthalmic Surg Lasers Imaging Retina. 2018 09 01; 49(9):698-706.
Score: 0.041
-
Bressler SB, Almukhtar T, Aiello LP, Bressler NM, Ferris FL, Glassman AR, Greven CM. Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network. Retina. 2013 Nov-Dec; 33(10):2080-8.
Score: 0.029